Tuberculous lymphadenopathy: a multicentre operational study of 6-month thrice weekly directly observed treatment
SETTING: Eight operational locations for the Revised National Tuberculosis Control Programme in six Indian states.OBJECTIVE: To assess the 6-month efficacy of an intermittent thrice-weekly directly observed treatment (DOT) regimen for tuberculous peripheral adenopathy and the need for prolongation o...
Saved in:
Published in | The international journal of tuberculosis and lung disease Vol. 17; no. 2; pp. 234 - 239 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Paris, France
International Union Against Tuberculosis and Lung Disease
01.02.2013
International Union against Tuberculosis and Lung Disease |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | SETTING: Eight operational locations for the Revised National Tuberculosis Control Programme in six Indian states.OBJECTIVE: To assess the 6-month efficacy of an intermittent thrice-weekly directly observed treatment (DOT) regimen for tuberculous peripheral adenopathy and the need
for prolongation of treatment to 9 months for non-resolution of lymphadenopathy.DESIGN: Patients aged >5 years with tuberculous lymphadenopathy were included in the study. Patients were evaluated for resolution at repeat visits following treatment. Those with poor resolution at 6 months
were randomised to extended treatment up to 9 months or observation without additional treatment.RESULTS: Resolution of lymphadenopathy was observed at the end of 6 months in 517/551 (93.8%) patients. There was a significant difference in response among patients with and those without
the presence of systemic symptoms. There was no association between treatment response and number, size, site, consistency and matting of lymphadenopathy. No differences in response were seen in the remaining 34 patients with or without extended treatment.CONCLUSION: The operational efficacy
of 6-month thrice-weekly DOT for peripheral tubercular lymphadenopathy was satisfactory. There was no evidence of additional benefits of prolonging treatment to 9 months. |
---|---|
Bibliography: | 1027-3719(20130201)17:2L.234;1- (R) Medicine - General ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
ISSN: | 1027-3719 1815-7920 |
DOI: | 10.5588/ijtld.12.0333 |